Search Results: All recruiting trials found

Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

33 trials found

Avapritinib (CS3007)
A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
1/2
       
Imatinib + PDR001
PDR001 Plus Imatinib for Metastatic or Unresectable GIST
1/2
       
Imatinib + Selinexor
Selinexor in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. (SeliGIST)
1/2
       
Imatinib
Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)
3
       
Imatinib
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
3
       
Anlotinib
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
2
       
Avelumab + Axitinib
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST)
2
       
Imatinib
The Stop-GIST Trial: Discontinuation of Imatinib in Patients With Oligo-metastatic GIST
2
       
Imatinib + Regorafenib
A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)
2
       
Lenvatinib
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST)
2
       
Nivolumab + Ipilimumab
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
2
       
Paclltaxel
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
2
       
Ponatinib (Iclusig)
POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST (POETIG)
2
       
Regorafenib (SDH)
Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)
2
       
Temozolomide
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor
2
       
DS-6157a
DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)
1
       
Imatinib
A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment
       
Imatinib + Sunitinib + Regorafenib
GIST: Assessment of Tumor Mutations and TKI Plasma Exposure
       
MAAT
Cognitive Impairment in GIST Patients on Tyrosine Kinase Inhibitor Therapy: Cognitive Behavioral Therapy to Improve Cognitive Symptoms (GIST-MAAT)
       
Surgery
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
       
EDO-S101
Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors
1/2
       
Regorafenib + Avelumab
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)
1/2
       
Pembrolizumab + Cyclophosphamide
Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC)
2
       
Rogaratinib
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
2
       
HER-2 B Cell Peptide
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
1
       
HQP1351
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
1
       
Imatinib + Ipilimumab
Ipilimumab and Imatinib Mesylate in Advanced Cancer
1
       
NB003
A Study of NB003 in Patients With Advanced Malignancies
1
       
CS1001 + Regorafenib
A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors
1/2
       
CB-839
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
2
       
Entrectinib
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)
2
       
LOXO-101
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors
2
       
Nivolumab + BMS-986016
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
1